Study Explores Liver Outcomes After HIV Treatment Switch - Takeaways - MDSpire

Study Explores Liver Outcomes After HIV Treatment Switch

PASO DOBLE sub-analysis reports steatosis differences at 96 weeks

  • March 5, 2026

  • 2 min

Share

  • 1

    Switching to Dovato (DTG/3TC) resulted in a lower proportion of steatotic liver disease compared to Biktarvy (BIC/FTC/TAF) in HIV-1 suppressed adults.

  • 2

    The PASO DOBLE study is the largest phase IV trial comparing DTG/3TC and BIC/FTC/TAF in adults with suppressed HIV-1.

  • 3

    At Week 96, SLD was reported in 49% of BIC/FTC/TAF recipients versus 29% of DTG/3TC recipients, indicating a significant difference.

  • 4

    Among participants with ≥5% weight gain, SLD occurred in 76% on BIC/FTC/TAF compared to 17% on DTG/3TC, highlighting treatment differences.

  • 5

    Dovato is approved for HIV-1 treatment in adults and certain adolescents without known resistance to integrase inhibitors or lamivudine.

Original Source(s)

Study Explores Liver Outcomes After HIV Treatment Switch

  • March 5, 2026

Related Content

The Connection Between Periodontal Microbiota and Liver Disease Development: Insights into the Oral-Gut-Liver Axis

Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS)

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.